Viracta Therapeutics Inc (VIRX) gains 1.61% for July 21

Equities Staff  |

Viracta Therapeutics Inc (NASDAQ: VIRX) shares gained 1.61%, or $0.18 per share, to close Wednesday at $11.38. After opening the day at $11.35, shares of Viracta fluctuated between $11.65 and $11.05. 150,163 shares traded hands a decrease from their 30 day average of 428,102. Wednesday's activity brought Viracta’s market cap to $422,114,607.

Viracta is headquartered in South San Francisco, California..

About Viracta Therapeutics Inc

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

Visit Viracta Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Viracta Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Viracta Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content